NRP2 acts as a risk factor for patients with BLCA, BRCA, HNSC, KIRP, OV, PAAD, STAD and UCEC, and as a protective factor for patients with THCA and CHOL. Here, NRP2 is linked to bladder transitional cell carcinoma.